Nakshathra Medi Science Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 31-10-2024
- Paid Up Capital ₹ 1.50 M
as on 31-10-2024
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.50 M
as on 31-10-2024
- Revenue -85.56%
(FY 2023)
- Profit -923.78%
(FY 2023)
- Ebitda 48.13%
(FY 2023)
- Net Worth -129.42%
(FY 2023)
- Total Assets -10.04%
(FY 2023)
About Nakshathra Medi Science
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹2.50 M.
Nandhiyal Bharathi, Indhu, Lakshmipathy Sugumaran, and One other member serve as directors at the Company.
- CIN/LLPIN
U51909TN2021PTC141267
- Company No.
141267
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Feb 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Nakshathra Medi Science?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nandhiyal Bharathi  | Director | 09-Feb-2021 | Current |
| Indhu | Additional Director | 14-Mar-2024 | Current |
| Lakshmipathy Sugumaran | Additional Director | 04-Mar-2023 | Current |
| Beeraka Rao | Additional Director | 21-Aug-2023 | Current |
Financial Performance of Nakshathra Medi Science.
Nakshathra Medi Science Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 85.56% decrease. The company also saw a substantial fall in profitability, with a 923.78% decrease in profit. The company's net worth observed a substantial decline by a decrease of 129.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nakshathra Medi Science?
In 2023, Nakshathra Medi Science had a public holding of 30.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 08 Feb 2023 | ₹2.50 M | Open |
How Many Employees Work at Nakshathra Medi Science?
Unlock and access historical data on people associated with Nakshathra Medi Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nakshathra Medi Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nakshathra Medi Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
